J7612 HCPCS code: Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg
J7612 is the HCPCS Level II code for levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg. In 2024 Medicare paid an average of $0.18 per service for J7612 across 1,262 services. Its Medicare coverage code is D (Special coverage instructions apply): May be covered when national or local coverage criteria are met. The NCCI unit limit is 900 per day on DME suppliers. Medicare volume rose 110% from 2022 to 2024 (601 to 1,262 services). In 2024, 302 suppliers billed Medicare for J7612 (purchases), serving 305 beneficiaries; Massachusetts, California, Pennsylvania accounted for 43% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 00 — Not separately priced by Medicare |
| BETOS category | D1G — Drugs administered through DME |
| Added | 2005-01-01 |
| Last action effective | 2009-07-01 |
Who bills J7612 (2024)
| Measure | Value |
|---|---|
| Suppliers billing rentals | — |
| Suppliers billing purchases | 302 |
| Referring clinicians | 308 |
| Medicare beneficiaries | 305 |
| States with claims | 17 |
| Share of services in top 3 states (Massachusetts, California, Pennsylvania) | 43% |
| Year | Suppliers | Beneficiaries |
|---|---|---|
| 2022 | 299 | 316 |
| 2023 | 309 | 319 |
| 2024 | 302 | 305 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J7612, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 601 | 404 | $0.27 | $0.20 |
| 2023 | 1,003 | 519 | $0.23 | $0.17 |
| 2024 | 1,262 | 528 | $0.26 | $0.18 |
States with the most J7612 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 602 | $0.17 |
| New York | 343 | $0.19 |
| Georgia | 32 | $0.15 |
| Louisiana | 31 | $0.18 |
| Texas | 21 | $0.18 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| DME suppliers | 900 | Clinical: Data |
| practitioner claims | 10 | Prescribing Information |
What changed for J7612
- 2005-01-01: J7612 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J7612?
J7612 is the HCPCS Level II code for levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg. Short descriptor: "Levalbuterol non-comp con".
How much does Medicare pay for J7612?
In 2024, the average Medicare payment was $0.18 per service (average allowed $0.26).
Does Medicare cover J7612?
Coverage code D — Special coverage instructions apply. May be covered when national or local coverage criteria are met.
How many units of J7612 can be billed per day?
900 on DME suppliers; 10 on practitioner claims (NCCI medically unlikely edits).
Related J76 codes
- J7601 — Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg
- J7604 — Acetylcysteine, inhalation solution, compounded product, administered through dme, unit dose form, per gram
- J7605 — Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms
- J7606 — Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms
- J7607 — Levalbuterol, inhalation solution, compounded product, administered through dme, concentrated form, 0.5 mg
- J7608 — Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram
- J7609 — Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg
- J7610 — Albuterol, inhalation solution, compounded product, administered through dme, concentrated form, 1 mg
- J7611 — Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg
- J7613 — Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg
- J7614 — Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg
- J7615 — Levalbuterol, inhalation solution, compounded product, administered through dme, unit dose, 0.5 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J7612
- Watch J7612 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J7612
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.